Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification ([SUKSES-D])

Samsung Medical Center

Status and phase

Terminated

Phase 2

Conditions

Small Cell Lung Cancer

Treatments

Drug: vistusertib (AZD2014)

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT03106155

2017-01-003

Details and patient eligibility

About

[Study Design] This study is a single arm, multi-center phase II study of vistusertib monotherapy in patients with relapsed small cell lung cancer (SCLC) harboring RICTOR amplification. Patients will receive vistusertib monotherapy (50 mg BID per os every 12 hours) until they demonstrate objective disease progression or they meet any other discontinuation criteria.

[Primary Objective] To investigate the efficacy of vistusertib monotherapy in patients with relapsed SCLC patients harboring RICTOR amplification as 2nd or 3rd line therapy

Enrollment

4 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

[Inclusion Criteria]

Provision of informed consent prior to any study specific procedures
Men and women aged at least 18 years
Small cell lung cancer harboring RICTOR amplification
Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 with no deterioration over the previous 2 weeks
Minimum life expectancy of 12 weeks
Patients must have acceptable bone marrow, liver and renal function measured within 14 days prior to administration of study treatment as defined below:
At least one measurable lesion that can be accurately assessed by imaging or physical examination at baseline and follow up visits.
No history of non-autologous bone marrow transplant.

Exclusion Criteria:

Participation in another clinical study with an investigational product during the last 21 days.
Prior chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents within 21 days of starting study treatment. Prior use of an investigational monoclonal antibody therapy within 3 months.
Major surgery within 4 weeks prior to study entry (excluding placement of vascular access), or minor surgery (excluding tumour biopsies) within 14 days of first dose of study treatment.
Exposure to strong or moderate inhibitors or inducers of CYP3A4/5, Pgp (MDR1) and BCRP if taken within the stated washout periods before the first dose of study treatment (see Appendix 1)
Exposure to specific substrates of the drug transporters OATP1B1, OATP1B3, MATE1 and MATE2K within the appropriate wash-out period
Any haemopoietic growth factors within 14 days prior to receiving study treatment.
Pre-treatment with other PI3K, AKT, dual PI3K/mTRO and mTOR inhibitors
Spinal cord compression and/or brain metastases unless asymptomatic or treated and stable off steroids for at least 4 weeks prior to start of study treatment.